RVMD FY 2023 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$20B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M-67.3% YoY

Gross Profit

$12M100.0% margin

Operating Income

-$487M-4207.1% margin

Net Income

-$436M-3768.3% margin

EPS (Diluted)

$-3.86

Cash Flow

Operating Cash Flow

-$351M

Free Cash Flow

-$358M

Stock-Based Comp.

$62M

Balance Sheet

Total Assets

$2.1B

Total Liabilities

$236M

Stockholders' Equity

$1.8B

Cash & Equivalents

$696M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$35M	-67.3%
Gross Profit	$12M	$35M	-67.3%
Operating Income	-$487M	-$258M	-88.6%
Net Income	-$436M	-$249M	-75.5%